Deep Genomics Awarded Stevies 2024 BioTechnology Company of the Year

Cambridge, MA– June 13, 2024 – Deep Genomics, the creator of BigRNA - the first AI foundation model for decoding RNA biology and designing therapeutics, today announced significant expansion milestones. The company celebrated the opening of its new office and lab facility in Cambridge, Massachusetts, the expansion ...

Remarks will highlight the latest deep learning technology from Deep Genomics for 

discovering RNA disease mechanisms and candidate therapeutics

TORONTO--(BUSINESS WIRE)--September 20, 2023 Deep Genomics, a leading AI drug development company focused on decoding biology to program life-changing medicines, announced today that its ...

O’Callaghan, a well-regarded life-science business leader with global experience and a significant track record of success, joins as part of plan to evolve Deep Genomics as a forward-integrated biopharmaceutical company 

Founder and current CEO Brendan Frey, Ph.D., F.R.S.C. to assume ...

TORONTO--(BUSINESS WIRE)--Deep Genomics, a leading AI drug development company focused on decoding biology to program life-changing medicines, today announced additions to its Board of Directors and Scientific Advisory Board which will advance its capabilities to develop oligonucleotides designed to boost protein production across ...

TORONTO AND CAMBRIDGE, MA, January 6, 2022. Deep Genomics, the leading AI RNA therapeutics company, today announced that its Founder and CEO, Brendan Frey, PhD, FRSC, will present at the 40^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 10 ...

Former Moderna CMO and COVID-19 vaccine lead brings experience building hugely successful mRNA therapeutics company to Deep Genomics. 

TORONTO AND CAMBRIDGE, MA, October 26, 2021. Deep Genomics, the leading AI therapeutics company, welcomes Tal Zaks, M.D., Ph.D., to its Strategic Advisory Board, effective ...